Intravesical therapy is given as an adjunct to transurethral resection of superficial bladder tumors to eradicate existing disease, inhibit tumor recurrence, and prevent progression to muscle invasion or metastasis. Of the available agents, bacillus Calmette-Guerin (BCG) fulfills these goals and appears superior to chemotherapeutic drugs.
